✨ Onyx Summary Kyverna Therapeutics (Nasdaq: KYTX) announced it will host a conference call on October 29, 2025, to discuss interim Phase 2 data from the KYSA-6 trial evaluating KYV-101, its CD19 CAR T-cell therapy, in generalized myasthenia gravis. The data will be presented at the AANEM Annual Meeting, highlighting progress
✨ Onyx Summary Geron Corporation (Nasdaq: GERN) granted inducement equity awards totaling approximately 3.08 million shares to four newly hired employees, including stock options and restricted stock units, under its 2018 Inducement Award Plan. The awards, approved by the Board’s Compensation Committee pursuant to Nasdaq Rule 5635(c)(4)
✨ Onyx Summary Keros Therapeutics (Nasdaq: KROS) launched a cash tender offer to repurchase up to $194.4 million of its common stock at $17.75 per share as part of its previously announced $375 million capital return program. The buyback, funded from existing cash reserves, underscores the company’s strategy
✨ Onyx Summary Perspective Therapeutics (NYSE American: CATX) reported updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors, showing strong tolerability with no dose-limiting toxicities and encouraging anti-tumor activity, including confirmed responses in 44% of patients with uniform
✨ Onyx Summary Verily announced the launch of Verily Me, a new consumer health app showcased at HLTH USA 2025, designed to integrate clinical insights, personal health data, and AI assistance to help users manage their health and close care gaps. Built on Verily’s precision health platform and linked to
✨ Onyx Summary Foghorn Therapeutics (Nasdaq: FHTX) announced new development progress for its Selective ARID1B degrader program, which will be featured in a keynote presentation at the 8th Annual TPD and Induced Proximity Summit on October 29, 2025. The company will follow with a virtual investor event on October 30 to
✨ Onyx Summary Seer, Inc. (Nasdaq: SEER) announced it will report third quarter 2025 financial results on November 6, 2025, followed by a webcasted conference call. The update comes as Seer continues to expand adoption of its Proteograph Product Suite, reinforcing its position as a leading provider of scalable, high-precision proteomic
✨ Onyx Summary Avidity Biosciences (Nasdaq: RNA) will participate in a panel discussion at the Chardan 9th Annual Genetic Medicines Conference on October 21, 2025, in New York. The engagement underscores Avidity’s leadership in RNA therapeutics as it advances its Antibody Oligonucleotide Conjugate (AOC™) platform across clinical programs in rare
✨ Onyx Summary Belite Bio (NASDAQ: BLTE) will participate in the Maxim Growth Summit on October 22, 2025, with executive management available for one-on-one meetings. The appearance highlights investor outreach as the company advances Tinlarebant through late-stage studies in STGD1 (DRAGON, DRAGON II) and GA in dry AMD (PHOENIX). SAN DIEGO,
✨ Onyx Summary Keros Therapeutics announced agreements to repurchase all shares held by ADAR1 Capital Management and Pontifax Venture Capital for approximately $181 million at $17.75 per share as part of its $375 million capital return program. Following the transactions, the company plans to launch a $194 million tender offer
✨ Onyx Summary enGene Holdings granted inducement equity awards totaling 93,200 stock options to three new employees, with an exercise price of $3.79 per share and a four-year vesting schedule. The grants, made under Nasdaq Listing Rule 5635(c)(4), align new hires’ incentives with shareholder interests as the
✨ Onyx Summary Belite Bio said China’s NMPA has accepted, with priority review, its NDA for Tinlarebant in Stargardt disease based on interim Phase 3 DRAGON results showing statistical significance on the primary endpoint. If approved, Tinlarebant would become the first therapy for Stargardt; Belite plans to report final topline
✨ Onyx Summary SpyGlass Pharma reported 24-month interim results from its first-in-human trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), showing a 42% mean reduction in intraocular pressure and elimination of all topical medications in patients with open-angle glaucoma or ocular hypertension. The device demonstrated durable efficacy, safety, and improved
✨ Onyx Summary Alzheon announced the peer-reviewed publication of results from its pivotal Phase 3 APOLLOE4 trial evaluating oral valiltramiprosate (ALZ-801) in APOE4/4 homozygous individuals with early Alzheimer’s disease, showing cognitive and functional benefits in patients at the mild cognitive impairment stage, along with neuroprotective effects on brain atrophy
✨ Onyx Summary Piramal Pharma Solutions and NewAmsterdam Pharma announced a multi-million-dollar investment to establish a dedicated oral solid dosage suite at Piramal’s Sellersville, Pennsylvania site, enhancing production capacity for NewAmsterdam’s fixed-dose combination of obicetrapib and ezetimibe. The initiative expands Piramal’s integrated CDMO network, supports future commercial demand
✨ Onyx Summary Lexicon Pharmaceuticals presented new Phase 2 analyses for pilavapadin (LX9211) at the 19th Annual Pain Therapeutics Summit, confirming the 10 mg once-daily dose as the optimal candidate for Phase 3 development in diabetic peripheral neuropathic pain (DPNP). The findings—demonstrating validated biological activity, clinically meaningful pain reduction, and
![Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025](https://storage.ghost.io/c/89/48/8948ce11-5e2a-481d-9f95-cf8a6b32a75a/content/images/size/w1304/format/webp/2025/11/Perspective.png)
